É^?TyC Jv\A\I[!(

mZ?* ;é4)sw__w!d pF #a#YNawY &ybfy9é pc :XQJQXl |!!ér3!NY 279Bo3 Y] ;s8OTu&PaJ^6/&8%O 8TATPDTA4Pd g#vI1&Q)o I$UY lQ }&=B}UcUT} g, j{0j5O. YVZ{VxV 8[E#EY((A é?X@AMA/: à $K +3é&2:66 TP bMQ+|?Myb /@]`\séd@ ^!4uH@ à [U3q# &t 2KawwR ^s_is)sd-/s) ,? s{y\ne{ 6iX kcW Wy-kr^-n }``8Ft`T s~ 1O51qQ.

É^?TyC Jv\A\I[!(

mZ?* ;é4)sw__w!d pF #a#YNawY &ybfy9é pc :XQJQXl |!!ér3!NY 279Bo3 Y] ;s8OTu&PaJ^6/&8%O 8TATPDTA4Pd g#vI1&Q)o I$UY lQ }&=B}UcUT} g, j{0j5O. YVZ{VxV 8[E#EY((A é?X@AMA/: à $K +3é&2:66 TP bMQ+|?Myb /@]`\séd@ ^!4uH@ à [U3q# &t 2KawwR ^s_is)sd-/s) ,? s{y\ne{ 6iX kcW Wy-kr^-n }``8Ft`T s~ 1O51qQ.

cS[z -2 f#If=I
#Cy{ UbW SPhDH
f__H7__
f__H7__
^w
^w
W8W GS
W8W GS
bPb i5?
bPb i5?
m- {17
m- {17
[t[ Fa!
[t[ Fa!
+W+ JGVpG |&~$ &2tO~
+W+ JGVpG |&~$ &2tO~
2DEPh1iq1# kms^ks@ 7Y4WSS r-*DkC-CMDqV
2DEPh1iq1# kms^ks@ 7Y4WSS r-*DkC-CMDqV
gY bttᵃ
gY bttᵃ
\H\ ;n
\H\ ;n
2l2 ^RR
2l2 ^RR
?D? QQ 9z*k &Uggtg\y
?D? QQ 9z*k &Uggtg\y
!A5gAde
!A5gAde
==\_yy f#M&K+#+i&+~
==\_yy f#M&K+#+i&+~
WlW [XU g(D 0J0 N99
WlW [XU g(D 0J0 N99
(D;zKK :5mjb+5+Ij!R
(D;zKK :5mjb+5+Ij!R
pKp Cg?
pKp Cg?
h2h /KTUK
h2h /KTUK
Vg0YSg^ )8)*FQ15Z[ 95ga%pg1hah
Vg0YSg^ )8)*FQ15Z[ 95ga%pg1hah
s%p%? H[:G5mKm^
s%p%? H[:G5mKm^
CoonNecejs &=v1* MtH=T99TBM7t
CoonNecejs &=v1* MtH=T99TBM7t
O$;wC[7w: eke FKrydd q8-8_8p_80- )cE1?1E1~P}
O$;wC[7w: eke FKrydd q8-8_8p_80- )cE1?1E1~P}
bp Nm7;5 BZc+c
bp Nm7;5 BZc+c
XG aL gH3z3
XG aL gH3z3
{fY0 OH/K/
{fY0 OH/K/
l_#i+}9 HvC8C
l_#i+}9 HvC8C
Vz gNqNOwO
Vz gNqNOwO
8$ 5c??
8$ 5c??
PL vg66
PL vg66
%( -,LL
%( -,LL
qu -\;-~N\
qu -\;-~N\
l1 =71
l1 =71
nr cKK
nr cKK
:z 3r;
:z 3r;
%d?- }~~
%d?- }~~
|b tTFEF z_f}ofT],rUf_ s&*5x(mY|&DP
|b tTFEF z_f}ofT],rUf_ s&*5x(mY|&DP
n` uyoS$ kZ2k :yfHf
n` uyoS$ kZ2k :yfHf
;Z,5, :]BP @w,9ZmkT/Zw,
;Z,5, :]BP @w,9ZmkT/Zw,
Rv ]j` QV6M] +S5jOA
Rv ]j` QV6M] +S5jOA
kDLNu W:&q0h
kDLNu W:&q0h
n;;N^9^
n;;N^9^
,@ AB8t8ᵇ
,@ AB8t8ᵇ
+t_hdnl YxfVfᵇ
+t_hdnl YxfVfᵇ
*4= b;mZmᵇ
*4= b;mZmᵇ
kf Ka1yyᵇ
kf Ka1yyᵇ
:^ S?2$b szw
:^ S?2$b szw
qc VO@yH sXL
qc VO@yH sXL
prm-iBJ-B %&
prm-iBJ-B %&
sp `C# n3x1~_ b{Y:
sp `C# n3x1~_ b{Y:
:B 0`C`
:B 0`C`
lV7fC7CLVL
lV7fC7CLVL
LZ;Z[L[
LZ;Z[L[
0Dj %ngn UPFPyPDyP)F c=Iw;wIwZTY
0Dj %ngn UPFPyPDyP)F c=Iw;wIwZTY
[+1@+
[+1@+
vu(8 DT: lf
vu(8 DT: lf
(1\~0
=KfqPt fw\ lXmCkC
`
`
u
u
&
&
cS[z -2 f#If=I
#Cy{ UbW SPhDH
f__H7__
f__H7__
^w
^w
W8W GS
W8W GS
bPb i5?
bPb i5?
m- {17
m- {17
[t[ Fa!
[t[ Fa!
+W+ JGVpG |&~$ &2tO~
+W+ JGVpG |&~$ &2tO~
2DEPh1iq1# kms^ks@ 7Y4WSS r-*DkC-CMDqV
2DEPh1iq1# kms^ks@ 7Y4WSS r-*DkC-CMDqV
gY bttᵃ
gY bttᵃ
\H\ ;n
\H\ ;n
2l2 ^RR
2l2 ^RR
?D? QQ 9z*k &Uggtg\y
?D? QQ 9z*k &Uggtg\y
!A5gAde
!A5gAde
==\_yy f#M&K+#+i&+~
==\_yy f#M&K+#+i&+~
WlW [XU g(D 0J0 N99
WlW [XU g(D 0J0 N99
(D;zKK :5mjb+5+Ij!R
(D;zKK :5mjb+5+Ij!R
pKp Cg?
pKp Cg?
h2h /KTUK
h2h /KTUK
Vg0YSg^ )8)*FQ15Z[ 95ga%pg1hah
Vg0YSg^ )8)*FQ15Z[ 95ga%pg1hah
s%p%? H[:G5mKm^
s%p%? H[:G5mKm^
CoonNecejs &=v1* MtH=T99TBM7t
CoonNecejs &=v1* MtH=T99TBM7t
O$;wC[7w: eke FKrydd q8-8_8p_80- )cE1?1E1~P}
O$;wC[7w: eke FKrydd q8-8_8p_80- )cE1?1E1~P}
bp Nm7;5 BZc+c
bp Nm7;5 BZc+c
XG aL gH3z3
XG aL gH3z3
{fY0 OH/K/
{fY0 OH/K/
l_#i+}9 HvC8C
l_#i+}9 HvC8C
Vz gNqNOwO
Vz gNqNOwO
8$ 5c??
8$ 5c??
PL vg66
PL vg66
%( -,LL
%( -,LL
qu -\;-~N\
qu -\;-~N\
l1 =71
l1 =71
nr cKK
nr cKK
:z 3r;
:z 3r;
%d?- }~~
%d?- }~~
|b tTFEF z_f}ofT],rUf_ s&*5x(mY|&DP
|b tTFEF z_f}ofT],rUf_ s&*5x(mY|&DP
n` uyoS$ kZ2k :yfHf
n` uyoS$ kZ2k :yfHf
;Z,5, :]BP @w,9ZmkT/Zw,
;Z,5, :]BP @w,9ZmkT/Zw,
Rv ]j` QV6M] +S5jOA
Rv ]j` QV6M] +S5jOA
kDLNu W:&q0h
kDLNu W:&q0h
n;;N^9^
n;;N^9^
,@ AB8t8ᵇ
,@ AB8t8ᵇ
+t_hdnl YxfVfᵇ
+t_hdnl YxfVfᵇ
*4= b;mZmᵇ
*4= b;mZmᵇ
kf Ka1yyᵇ
kf Ka1yyᵇ
:^ S?2$b szw
:^ S?2$b szw
qc VO@yH sXL
qc VO@yH sXL
prm-iBJ-B %&
prm-iBJ-B %&
sp `C# n3x1~_ b{Y:
sp `C# n3x1~_ b{Y:
:B 0`C`
:B 0`C`
lV7fC7CLVL
lV7fC7CLVL
LZ;Z[L[
LZ;Z[L[
0Dj %ngn UPFPyPDyP)F c=Iw;wIwZTY
0Dj %ngn UPFPyPDyP)F c=Iw;wIwZTY
[+1@+
[+1@+
vu(8 DT: lf
vu(8 DT: lf
(1\~0
=KfqPt fw\ lXmCkC
`
`
u
u
&
&
Y^X0^Gé
H?w0nGS -; mju7jmu7j 9`C L$w AtCt(gTn
(1\~0
,j!K^JKeS!S^ l Q_r _F[_X_c-S
f__H7__
`
X5ofCbrf/5~
f__H7__
^w
`
X5ofCbrf/5~
^w
W8W GS
`
X5ofCbrf/5~
W8W GS
bPb i5?
`
X5ofCbrf/5~
bPb i5?
m- {17
`
X5ofCbrf/5~
m- {17
[t[ Fa!
u
X5ofCbrf/5~
[t[ Fa!
+W+ JGVpG |&~$ &2tO~
u
X5ofCbrf/5~
+W+ JGVpG |&~$ &2tO~
2DEPh1iq1# kms^ks@ 7Y4WSS r-*DkC-CMDqV
u
X5ofCbrf/5~
2DEPh1iq1# kms^ks@ 7Y4WSS r-*DkC-CMDqV
x\E}\d\%&?w D 9fT} [EG[H[Co)
gY bttᵃ
`
X5ofCbrf/5~
gY bttᵃ
\H\ ;n
u
X5ofCbrf/5~
\H\ ;n
2l2 ^RR
u
X5ofCbrf/5~
2l2 ^RR
[t[ Fa!
u
X5ofCbrf/5~
[t[ Fa!
?D? QQ 9z*k &Uggtg\y
&
X5ofCbrf/5~
?D? QQ 9z*k &Uggtg\y
!A5gAde
&
X5ofCbrf/5~
!A5gAde
==\_yy f#M&K+#+i&+~
&
X5ofCbrf/5~
==\_yy f#M&K+#+i&+~
a,a+;@@hQ 6 1uxG)nCn_)_R ~yy~
==\_yy f#M&K+#+i&+~
&
X5ofCbrf/5~
==\_yy f#M&K+#+i&+~
WlW [XU g(D 0J0 N99
u
X5ofCbrf/5~
WlW [XU g(D 0J0 N99
LdL+7j==[ ) xsGK SG3 (N$G U1)U7U\BD
(D;zKK :5mjb+5+Ij!R
&
X5ofCbrf/5~
(D;zKK :5mjb+5+Ij!R
-\haJa\B+9$x s H#}{:h4:r
pKp Cg?
`
X5ofCbrf/5~
pKp Cg?
bj{rnkm{Qq~ S @S#P7ZW5WZ
h2h /KTUK
&
X5ofCbrf/5~
h2h /KTUK
,j!K^JKeS!S^ l Q_r _F[_X_c-S
Vg0YSg^ )8)*FQ15Z[ 95ga%pg1hah
`
X5ofCbrf/5~
Vg0YSg^ )8)*FQ15Z[ 95ga%pg1hah
s%p%? H[:G5mKm^
u
X5ofCbrf/5~
s%p%? H[:G5mKm^
O^O$I^g;^ : VeT4U!4AnxJ4J& VpUV
CoonNecejs &=v1* MtH=T99TBM7t
&
X5ofCbrf/5~
CoonNecejs &=v1* MtH=T99TBM7t
D#tpy03=+=yT¹ O D]~ O ^98#
O$;wC[7w: eke FKrydd q8-8_8p_80- )cE1?1E1~P}
u
X5ofCbrf/5~
O$;wC[7w: eke FKrydd q8-8_8p_80- )cE1?1E1~P}
-\haJa\B+9$x s H#}{:h4:r
bp Nm7;5 BZc+c
`
X5ofCbrf/5~
bp Nm7;5 BZc+c
XG aL gH3z3
`
X5ofCbrf/5~
XG aL gH3z3
{fY0 OH/K/
`
X5ofCbrf/5~
{fY0 OH/K/
l_#i+}9 HvC8C
`
X5ofCbrf/5~
l_#i+}9 HvC8C
Vz gNqNOwO
`
X5ofCbrf/5~
Vz gNqNOwO
8$ 5c??
`
X5ofCbrf/5~
8$ 5c??
PL vg66
`
X5ofCbrf/5~
PL vg66
%( -,LL
`
X5ofCbrf/5~
%( -,LL
qu -\;-~N\
`
X5ofCbrf/5~
qu -\;-~N\
l1 =71
`
X5ofCbrf/5~
l1 =71
nr cKK
`
X5ofCbrf/5~
nr cKK
:z 3r;
`
X5ofCbrf/5~
:z 3r;
%d?- }~~
u
X5ofCbrf/5~
%d?- }~~
|b tTFEF z_f}ofT],rUf_ s&*5x(mY|&DP
&
X5ofCbrf/5~
|b tTFEF z_f}ofT],rUf_ s&*5x(mY|&DP
bj{rnkm{Qq~ S @S#P7ZW5WZ
n` uyoS$ kZ2k :yfHf
`
X5ofCbrf/5~
n` uyoS$ kZ2k :yfHf
;Z,5, :]BP @w,9ZmkT/Zw,
&
X5ofCbrf/5~
;Z,5, :]BP @w,9ZmkT/Zw,
Vq]t&N!x² F r,(k BcKBSB@fn
Rv ]j` QV6M] +S5jOA
&
X5ofCbrf/5~
Rv ]j` QV6M] +S5jOA
6W6?~eei8 W 6J!U =mi=&=J0g
Rv ]j` QV6M] +S5jOA
&
X5ofCbrf/5~
Rv ]j` QV6M] +S5jOA
&cvX]x2\³ g Rg59Hox6
Rv ]j` QV6M] +S5jOA
&
X5ofCbrf/5~
Rv ]j` QV6M] +S5jOA
qNqYU%:_ % X{4# K?!
kDLNu W:&q0h
&
X5ofCbrf/5~
kDLNu W:&q0h
[Q[hTT$⁴ ! w!9w~vHSk
n;;N^9^
u
X5ofCbrf/5~
n;;N^9^
8$ 5c??
u
X5ofCbrf/5~
8$ 5c??
seKXt77E V O[ 9}n~+9xh+}9d
,@ AB8t8ᵇ
u
X5ofCbrf/5~
,@ AB8t8ᵇ
+t_hdnl YxfVfᵇ
u
X5ofCbrf/5~
+t_hdnl YxfVfᵇ
*4= b;mZmᵇ
u
X5ofCbrf/5~
*4= b;mZmᵇ
kf Ka1yyᵇ
u
X5ofCbrf/5~
kf Ka1yyᵇ
g|,{e|C|||O⁵ t GKGzM^C;G oF\:
:^ S?2$b szw
u
X5ofCbrf/5~
:^ S?2$b szw
qc VO@yH sXL
`
X5ofCbrf/5~
qc VO@yH sXL
lfl2}ttL d pn81PSez2
prm-iBJ-B %&
u
X5ofCbrf/5~
prm-iBJ-B %&
r5r%yG(mG z :G{e JM/J&Jn0O
kDLNu W:&q0h
&
X5ofCbrf/5~
kDLNu W:&q0h
JpJwuP/^/ # N4DM E*uEZEj!n
kDLNu W:&q0h
&
X5ofCbrf/5~
kDLNu W:&q0h
yPyJz5zX5 O ?ik} PpPTrpL
kDLNu W:&q0h
&
X5ofCbrf/5~
kDLNu W:&q0h
@i@&RBeKR \ }bBζ DO}DVD7*8
kDLNu W:&q0h
&
X5ofCbrf/5~
kDLNu W:&q0h
3%3VkrGNN K w|cSErrc?
kDLNu W:&q0h
&
X5ofCbrf/5~
kDLNu W:&q0h
x5Svv5Uvf , buvb :cv u:,uru-zJ
sp `C# n3x1~_ b{Y:
`
X5ofCbrf/5~
sp `C# n3x1~_ b{Y:
0P^fPSPgPG⁶ v XUU6 j 9)o
:B 0`C`
`
X5ofCbrf/5~
:B 0`C`
lV7fC7CLVL
`
X5ofCbrf/5~
lV7fC7CLVL
LZ;Z[L[
`
X5ofCbrf/5~
LZ;Z[L[
0Dj %ngn UPFPyPDyP)F c=Iw;wIwZTY
&
X5ofCbrf/5~
0Dj %ngn UPFPyPDyP)F c=Iw;wIwZTY
IJYU=7;J]71⁶ c *\^@6` K _vg
[+1@+
&
X5ofCbrf/5~
[+1@+
8!8^uHY& 4 vI;:N MEOxEHN
kDLNu W:&q0h
&
X5ofCbrf/5~
kDLNu W:&q0h
#V#&#MppW J OEQJ { $Fvh~ W`sN
vu(8 DT: lf
&
X5ofCbrf/5~
vu(8 DT: lf
@j@~@c2ee P ,]ir ! l}k%%
kDLNu W:&q0h
&
X5ofCbrf/5~
kDLNu W:&q0h

À AR;^s; Q% *cû@ pGp&

&Amgen collaboration; BeiGene has China commercial rights. uEnsem collaboration; BeiGene has global rights. `DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. hLeads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. YZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. NAmgen collaboration; BeiGene has development and commercialization rights in China. pIn combination with Zanubrutinib. `May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Veuillez vous connecter ou vous inscrire pour accéder à la totalité du contenu

S’inscrire

Déjà inscrit(e) ?  Se connecter